Prothena Corp Public Ltd Co (PRTA) stock

PRTANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3017% below fair value

$8.16−0.07 (-0.85%)

Close on Nov 13, 2026Market cap $418.91MP/E –Yield –

Prothena Corp Public EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Prothena Corp Public's EV/EBITDA was 13.5× on Jul 29, 2022.

Period	Period end	Value	Change (pts)
2022	Jul 29, 2022	13.5×	−8.8
2021	Dec 31, 2021	22.4×	–

Parsed from the XBRL in Prothena Corp Public's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is PRTA.

Revenue growth347.4% · median 55.7%

Operating margin-64.6% · median -185.3%

Net margin-45.4% · median -161.2%

Advertisement
300 × 250

See a number that looks wrong?